LumaCyte
PrivateLast Round
Series B
Sep 6, 2023
Total Funding Raised
$12.67M
Company Overview
LumaCyte operates in Healthcare & Life Sciences and is based in Charlottesville, Virginia. Its latest recorded funding round was a Series B round in September 2023.
LumaCyte is a bioanalytics instrumentation company that produces label-free, single cell analysis instrumentation for research and biomanufacturing applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery, Precision Medicine, Healthcare Analytics
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription, Subscription SaaS, Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
LumaCyte Comparables
Compare LumaCyte with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ThinkCyte | 86% | |
| LevitasBio | 83% | |
| NanoCellect Biomedical | 83% |
For institutional investors. Book with your work email.
LumaCyte Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 6, 2023 | ||||
| Series A | Mar 2, 2022 | ||||
| Grant | Aug 30, 2019 | ||||
| Grant | Jan 9, 2019 | ||||
| Grant | Apr 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
LumaCyte Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Carnegie Mellon University Investment Office | Grant |
| Genentech | Grant |
| Rensselaer Polytechnic Institute | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 17, 2026
Grew 20% QoQ, from 20 to 24 employees.
- Nov 27, 2023
Grew 20% QoQ, from 20 to 24 employees.
For institutional investors. Book with your work email.
LumaCyte Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about LumaCyte's valuation, stock price, and market status.
Is LumaCyte a public or private company?
LumaCyte is a private company.
What is the current stock price of LumaCyte?
LumaCyte is a private company, so its shares have no public market price. Caplight tracks LumaCyte's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is LumaCyte worth (valuation)?
Valuation information for LumaCyte is not publicly available.
Can I buy LumaCyte stock?
LumaCyte shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was LumaCyte's last funding round?
LumaCyte's most recent funding round was Series B on September 6, 2023.
Who are the main investors in LumaCyte?
Key investors in LumaCyte include Carnegie Mellon University Investment Office, Genentech, Rensselaer Polytechnic Institute.
Will LumaCyte IPO soon?
No public IPO plans have been announced for LumaCyte.
How can I track LumaCyte secondary market activity?
Caplight tracks bids, offers, and trades in LumaCyte's shares on secondary markets.